$0.34

0.01 (2.86%)

General Information

Immuron Limited
IMC
http://www.immuron.com
Biotechnology
28
79

Current Price Data+

Current Price $0.340
Open $0.340
High $0.340
Low $0.340
Last Close $0.350
Volume 3216
Price Movement $0.01 ( 2.86% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Stock Price

Company Overview

Business Description

Immuron Limited (IMC) is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Company's product development has driven biopharmaceutical Company focused on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases.The company has two products HyperImmune Products and Research and Development

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2015 A -3.4 -4.6 0.0% 0.0 0.0 0.0% 0.0%
2014 A -2.5 -6.1 0.0% 0.0 0.0 0.0% 0.0%
2013 A -3.5 -24.9 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2013 A 2014 F 2015 F 2013 A 2014 F 2015 F 2013 A 2014 F 2015 F
CSL (CSL) $50,972M 0.3109 0.0444 0.2592 29.7391 28.4739 22.6123 1.45% 1.51% 2.29%
Immuron (IMC) $28M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast (MSB) $828M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $430M 1.8016 0.1736 0.0347 17.7013 15.0826 14.5767 3.81% 4.64% 4.81%
Sirtex Medical (SRX) $1,773M 0.6876 0.4568 0.4482 44.4046 30.4806 21.0473 0.65% 0.96% 1.39%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 7.85 0.00
Market 1.15 15.60 1.17 0.91
Sector 0.49 15.30 3.30 0.69

Directors

Name Position Start Date
Dr Roger Aston Non-Executive Chairman 25 May 2012
Mr Daniel Pollock Non-Executive Director 11 Oct 2012
Mr Stephen Anastasiou Non-Executive Director 28 May 2013
Mr Peter Anastasiou Vice Chairman 21 May 2015

Management

Name Position
Thomas Liquard Chief Executive Officer
Phillip Hains Joint Company Secretary
Peter Vaughan Joint Company Secretary

Substantial Shareholders

Holding Name
10,022,360 (13.37%) Grandlodge Pty Ltd

Calendar of Events

Date Event
23 February 2017 Report (Interim)
26 August 2016 Report (Prelim)
26 August 2016 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.